If TG Therapeutics sat on your watchlist instead of in your portfolio, the move over this stretch may feel expensive in hindsight. For TG Therapeutics shareholders, the return from the start of the year was 92.8%, including dividends. That outcome arrived in a year when bulls pointed to BRIUMVI’s expansion potential and bears highlighted dependence on a single therapy. If you rewind to January, how confident would you have been that concentration in one drug was a strength rather than a vulnerability?
The move put TG Therapeutics in the middle of this trade. Scan 34 healthcare AI stocks for other companies exposed to it.
The Argument TG Therapeutics Investors Were Really Weighing
The shares cost US$29.81 at the start of the period, and the live debate was whether TG Therapeutics could grow into a far higher valuation or whether expectations already stretched too far.
Bulls leaned on an optimistic narrative with a Fair Value of US$40.5, a price implied by assumptions that BRIUMVI, including a planned subcutaneous version, would reach a much larger multiple sclerosis market and support rising profit margins.
Bears ran with a Fair Value of US$11, built on the risk that heavy dependence on BRIUMVI plus rising pricing pressure and future biosimilar competition would squeeze both revenue potential and margins.
What The Evidence Did To The TG Therapeutics Argument
The clearest data point in this stretch was TG Therapeutics lifting 2026 revenue guidance to about US$950 million while BRIUMVI U.S. sales reached US$227.7 million in Q2 2026. That supported the more optimistic view on demand and market reach. At the same time, Q2 net margin fell to 3.2% from 20.0% a year earlier, so the profitability part of the bull case remained unproven. Overall, the evidence pointed in both directions.
The lesson is simple. When a story hinges on “scale will fix margins,” do not stop at revenue. Track net income and margin side by side with guidance to see whether additional sales are actually turning into lasting earnings power.
What TG Therapeutics’ Run Now Asks You To Believe
TG Therapeutics now trades at US$56.44, and the selected Narrative’s Fair Value sits below that market price. The Narrative argues that the recent move leaves you paying for a lot going right on BRIUMVI, while expenses, pipeline spend and governance questions still need to prove they are under control.
The live question is what must keep working for this level to hold. A buyer at today’s price would need to assume TG Therapeutics can turn BRIUMVI’s concentrated revenue stream and newer programs into durable, high margin earnings while keeping operating, manufacturing and governance related costs from overwhelming that progress.
"The main thing that has to go right is that the company converts the current BRIUMVI patient base, lifecycle programs, and emerging pipeline into durable, high margin recurring earnings while managing rising operating costs and any governance overhang from the ongoing investigation."
One Narrative disagrees with today's price. → See where this Narrative says TG Therapeutics should trade
Looking One Step Beyond TG Therapeutics
TG Therapeutics asks you to weigh a concentrated bet on one drug. It also invites comparison with a very different operating model.
Some healthcare giants spread risk across many therapies and devices. Instead of one key asset, they manage a broad mix of platforms.
That breadth can support larger research programs, deal making and intricate manufacturing projects. It may also absorb pricing pressure, policy changes and legal costs differently.
If you are weighing TG Therapeutics, that contrast matters. A diversified operator facing similar forces might show another way healthcare exposure can look.
It is written up in full, assumptions and all. → Explore the Narrative that puts this company 19% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com